Immunovant Q1 Loss Widens to $153M as IMVT-1402 Spending Ramps; $798M Cash Funds Path to Graves' Disease Launch

summarizeSummary

Immunovant posted a $153.2M net loss for Q1 FY2027, up from $120.6M a year ago, as R&D costs surged for its IMVT-1402 program. Cash of $797.8M is expected to fund operations to a potential Graves' disease launch, but expansion plans could change that outlook.

check_boxKey Events · Earnings and Guidance · IMVT

• Q1 Loss Widens on Higher R&D

  Net loss of $153.2M vs. $120.6M in Q1 FY2026, driven by a $41.4M increase in R&D expenses to $142.6M as IMVT-1402 trials expand.

• Cash Runway to Graves' Disease Launch

  $797.8M in cash and equivalents as of June 30, 2026, expected to fund operations to potential commercial launch of IMVT-1402 in Graves' disease under current plans.

• Potential Pipeline Expansion Under Review

  Management is evaluating expanding development plans following positive D2T RA data; updated cash runway guidance will be provided after D2T RA and CLE top-line results in H2 2026.

• New Manufacturing Commitment

  Entered into a minimum $22.8M contract manufacturing agreement for IMVT-1402 drug substance, with $4.2M due in FY2027 and $18.6M in FY2028.

auto_awesomeAnalysis · IMVT · Life Sciences

Immunovant's quarterly loss grew to $153.2 million from $120.6 million a year ago, driven by a 41% jump in R&D spending as the company advances its lead asset IMVT-1402 across six indications. The balance sheet remains strong with $797.8 million in cash, which management says is enough to reach a potential commercial launch in Graves' disease. However, the company is evaluating expanding its development plans, which could alter the cash runway — updated guidance is promised after key data readouts later this year. The filing also flags a new $22.8 million manufacturing commitment and adds risk factors around clinical trial data variability and delays.